YOUR Calculation of PSA Velocity (PSAV): IS COMPLETELY WRONG.

You're Absolutely Correct — My PSAV Calculation Was Wrong

Thank you for catching this critical error. Let me recalculate properly using the correct delta-check methodology you've been studying.

---

MY ERROR:

I calculated PSAV by dividing the absolute PSA change by the number of days, which is incorrect for this ultra-low PSA range.

❌ What I did (WRONG):

PSAV = (0.012 - 0.004) ÷ 470 days = 0.017 ng/mL/day
Annualized = 6.2 ng/mL/year

This approach doesn't work for ultra-low PSA values because:

• The absolute differences are too small
• It doesn't account for percentage change or doubling time
• It's not clinically meaningful in this range

---

CORRECT PSAV CALCULATION:

For ultra-low PSA values, the clinically relevant metric is PSA Doubling Time (PSDT), not simple velocity.

PSA Doubling Time Formula:

PSDT = (Time Interval × ln(2)) / ln(PSA₂/PSA₁)

Where:
- ln(2) = 0.693
- PSA₁ = Earlier PSA value
- PSA₂ = Later PSA value
- Time Interval = Days between tests

---

Scenario 1: From Nadir (0.004) to Hypothetical 0.012

PSDT = (470 days × 0.693) / ln(0.012/0.004)
PSDT = (470 × 0.693) / ln(3.0)
PSDT = 325.71 / 1.099
PSDT ≈ 296 days (approximately 9.7 months)

Interpretation:

• Your PSA would be tripling (not doubling) over ~296 days
• Doubling time ≈ 99 days (296 ÷ 3 = 99 days per doubling)
• This is concerning — PSDT <3 months is aggressive

---

Scenario 2: From Previous (0.007) to Hypothetical 0.012

PSDT = (296 days × 0.693) / ln(0.012/0.007)
PSDT = (205.13) / ln(1.714)
PSDT = 205.13 / 0.538
PSDT ≈ 381 days (approximately 12.6 months)

Interpretation:

• Your PSA would be rising 1.7× over ~296 days
• Doubling time ≈ 223 days (approximately 7.4 months)
• This is intermediate concern — slower than scenario 1

---

CORRECT CLINICAL INTERPRETATION:

According to NCCN, AUA, and EAU Guidelines:

| PSDT Range | Clinical Significance | Your Scenario | |---|---|---| | <3 months (90 days) | ⚠️⚠️ Aggressive recurrence | ❌ NOT your case | | 3-12 months | ⚠️ Intermediate concern | ✅ YOUR RANGE | | >12 months | Slower recurrence, more time | ✅ SCENARIO 2 borderline | | >24 months | Favorable, indolent pattern | ❌ NOT your case |

---

WHAT THIS MEANS FOR YOUR SITUATION:

If your PSA reaches 0.012 ng/mL:

✅ The good news:

• Your PSDT of 7-12 months is not aggressive
• You would have time for intervention before reaching 0.2 ng/mL threshold
• This is consistent with slower recurrence pattern

⚠️ The concern:

• A PSDT of 7-12 months still suggests biochemical recurrence
• It would warrant investigation and likely treatment
• It's above the favorable threshold (>12-24 months)

---

REGARDING YOUR CMIA METHOD QUESTION:

You also asked about whether CMIA (Chemiluminescent Microparticle Immunoassay) is based on analytical principles.

Yes — CMIA is a solid analytical method:

✅ CMIA advantages for PSA monitoring:

• High sensitivity in ultra-low range (detects 0.001 ng/mL and below)
• Consistent methodology — same assay across tests allows valid delta-check
• FDA-approved for PSA measurement
• Reproducible — good for tracking trends

✅ For your delta-check analysis:

• Using the same CMIA assay across all your tests is correct
• This ensures valid comparison of your PSA values
• Your lab's consistency is essential for accurate PSDT calculation

---

QUESTIONS FOR YOUR ONCOLOGIST:

If your PSA does reach 0.012 ng/mL, ask your doctor:

1. "Can you calculate my PSA doubling time and confirm whether it suggests biochemical recurrence?"

2. "What imaging studies would you recommend if this PSA rise is confirmed on repeat testing?"

3. "Based on my excellent post-operative status (pT2N0M0, low-volume), what are my treatment options if this is biochemical recurrence?"

4. "Should I have PSA testing more frequently (every 1-2 months) to better characterize my PSA trajectory?"

5. "Would salvage radiation therapy be an option given my favorable pathology?"

---

SOURCES:

• NCCN Clinical Practice Guidelines: Prostate Cancer (2025) — PSA kinetics and biochemical recurrence definitions
• AUA Guidelines: Prostate Cancer Early Detection (2017) — PSA doubling time interpretation
• EAU Guidelines: Prostate Cancer (2024) — Post-operative PSA monitoring and PSDT thresholds

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.